Leith Wheeler Investment Counsel Ltd. Has $26.19 Million Position in Henry Schein, Inc. $HSIC

Leith Wheeler Investment Counsel Ltd. lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 2.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 355,314 shares of the company’s stock after selling 8,079 shares during the period. Henry Schein accounts for 2.2% of Leith Wheeler Investment Counsel Ltd.’s holdings, making the stock its 12th biggest position. Leith Wheeler Investment Counsel Ltd. owned about 0.31% of Henry Schein worth $26,187,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in shares of Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after purchasing an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after buying an additional 229 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Henry Schein during the 1st quarter worth about $676,000. Cetera Investment Advisers grew its stake in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after buying an additional 637 shares during the last quarter. Finally, First Trust Advisors LP grew its stake in Henry Schein by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after buying an additional 1,669 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $86.20 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $9.82 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 1.69 and a beta of 0.81. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.34. The company has a 50-day simple moving average of $79.85 and a two-hundred day simple moving average of $77.79.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the prior year, the business posted $1.15 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Transactions at Henry Schein

In related news, Director William K. Daniel acquired 10,000 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the purchase, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on HSIC. Morgan Stanley restated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, June 11th. Citigroup assumed coverage on Henry Schein in a report on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target for the company. Finally, BMO Capital Markets began coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $87.64.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.